Sign in: Staff/Students
New research has found that previous infection, whether it was symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
The preprint study was led by University of Oxford, in collaboration with the Universities of Liverpool, Sheffield, Newcastle and Birmingham with support from the UK Coronavirus Immunology Consortium.
The Protective Immunity from T cells to COVID-19 in Health workers study (PITCH) examined how the immune system responds to COVID-19 in 78 healthcare workers who had experienced either symptomatic or asymptomatic disease (66 vs 12). An additional 8 patients who experienced severe disease were included for comparison.
Blood samples were taken monthly from 1–6 months post infection to examine different elements of the immune response. This included different types of antibodies – such as Spike-specific and Nucleocapsid-specific antibodies which are produced to target different parts of the virus, alongside B cells, which manufacture antibodies and keep the body’s memory of the disease, and several types of T cell.
The preprint report details a highly complex and variable immune response following COVID-19 infection. The University of Liverpool’s Dr Lance Turtle is a co-author on the study, which has been posted on Research Square.
The researchers used a new machine learning approach – nicknamed SIMON – to identify detailed patterns in the data and to see if initial disease severity and the early immune response could predict longer-term immunity.
They found an early immune signature, detectable one month post infection and linked to both cellular and antibody immunity, which predicted the strength of immune response measured at 6 months post infection. This is the first time that such a signature has been found and improves understanding of the development of lasting immunity. When serum samples (containing antibodies) obtained at 1 and 6 months post infection were tested, the majority of samples from people who produced a weak immune response signature failed to show any neutralising antibodies against the Alpha variant, with none mounting a neutralising antibody response against the Beta variant. This raises the possibility that the immune memory of these individuals does not provide sufficient protection to prevent reinfection by these variants.
While the majority of people who had symptomatic disease did have measurable immune responses at six months post infection, a significant minority (17/66; 26%) did not. The vast majority of people who experienced asymptomatic disease (11/12; 92%) did not exhibit a measurable immune response at six months post infection. This implies that people who have previously been infected with COVID-19 should not assume they are automatically protected against reinfection and highlights the importance of everyone getting their COVID vaccination when they are offered it.
Health Minister Lord Bethell said: “This powerful study addresses the mysteries of immunity and the lessons are crystal clear. You need two jabs to protect yourself and the ones you love. I call on anyone invited to get vaccinated to step forward and finish the job so we can all get out of this.”
Key findings from the PITCH study:
Understanding the strength and durability of the immune response to natural COVID infection remains highly relevant as it will help us reduce reinfections, better understand immune responses to vaccination and tackle new variants of concern. Further research will continue to deepen our understanding of the immune responses over the longer term and what it means for protection against COVID-19 in the real world.
This study reinforces how important it is that everyone gets their COVID vaccination when offered. COVID-19 vaccines generate higher immune responses than natural infection, underlining the need for everyone to get vaccinated for maximum protection against this disease and in particular against Variants of Concern.
Tomic et al. 2021. Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Research Square, doi: 10.21203/rs.3.rs-612205/v1 https://www.researchsquare.com/article/rs-612205/v1
All recent news
Chemistry student wins European Undergraduate Placement of the Year award
Minister for Small Business visits as Help to Grow rolled out by Management School
Prof Tom Solomon elected Vice President of the Academy of Medical Sciences
Liverpool Bayesian model helps calculate COVID-19 R number
Event: Live, interactive family show on COVID with Tom Solomon
We are delighted to announce the election of our new Vice President (International), Professor Tom Solomon CBE FMedSci @RunningMadProf
Read more here: http://ow.ly/snrJ50GuFog
A Bayesian statistical model created by @LivUniEEE researchers is one of the models being used by the UK Government to estimate the UK’s COVID -19 R number. #LivUniCovid
Read more: https://bit.ly/3AZJdTb
We welcomed Minister for Small Business, Paul Scully MP (@scullyp) this afternoon to discuss @UoLManSchool's successful roll out of the #HelptoGrow scheme